New Chinese medicine drugs continue to accelerate the pace of listing, where will the future foothold?

【Pharmaceutical Network Market Analysis】Traditional Chinese medicine is a great creation of the Chinese nation, but also an important part of China's medical and health system, with unique value
.
In recent years, with the promotion of favorable policies such as speeding up the review of traditional Chinese medicines, pharmaceutical companies have continued to increase investment in research and development, which has ushered in a new period of development in the research and development of new Chinese medicines, and new products have been listed
one after another.
In 2021, a total of 12 new Chinese medicine drugs were approved for marketing, a new high in nearly 5 years, covering multiple disease fields
such as respiratory system and digestive system.
Entering 2022, there are still a number of new Chinese medicine drugs to accelerate the listing
.
According to the news of the State Food and Drug Administration on October 9, Jiangsu Kangyuan Pharmaceutical Co.
, Ltd.
Class 3.
2 Chinese medicine new drug scattered cold wet granules were approved for use in cold and wet lungs caused by blight
.
The listing of cold and wet particles will provide another treatment option
for the treatment of blight.
On September 15, the State Food and Drug Administration announced that it approved the application for
the listing and registration of 1.
2 class 1.
2 Chinese medicine innovative drug Guangqiancao total flavone capsules.
The new drug mainly extracts the total flavonoids obtained from Guangqian Herb, which can be used in the treatment
of ureteral stones in patients with damp heat deficiency syndrome in traditional Chinese medicine.
The holder of the drug marketing authorization is Wuhan Guanggu Renfu Biopharmaceutical Co.
, Ltd.

On January 10, the State Food and Drug Administration released the news that the bureau conditionally approved the listing
of the 1.
2 class 1.
2 innovative drug epimedium softgels through the priority review and approval procedure.
The listing of this variety offers new treatment options
for hepatocellular carcinoma patients.
The holder of the drug marketing authorization is Beijing Yannuoji Pharmaceutical Technology Co.
, Ltd.

In addition, there are a number of blockbuster Chinese medicine innovative drugs in the clinical trial stage, and the market can be expected
.
For example, Kangchen Pharmaceutical announced at the end of September that the company's Phase III clinical trial of the innovative medicine medicine Golden Herb Tablets was approved for ethical review, marking further substantial progress in the Phase III clinical research of Golden Herb Tablets, and the current research of the project is progressing smoothly, and it is expected to complete the first case of subject enrollment
in the near future.
It is reported that the product is the first "pelvic inflammatory disease sequelae chronic pelvic pain" indication of accurate re-approval of traditional Chinese medicine class 1.
2 innovative drugs, the current pelvic inflammatory disease sequelae chronic pelvic pain in China has not yet been approved for this indication
.
In the industry's view, Chinese medicine innovative drugs are undoubtedly a piece of self-reserved land
on the biomedical sector.
However, in the long run, the foothold of innovative Chinese medicine drugs is still in terms of performance, and it is necessary to see which varieties can enter the medical insurance directory and the basic drug directory, and whether they can really create considerable revenue for the company
.
Recently, the 2022 National Medical Insurance Catalogue Pass Form Review List has been announced, and a total of 35 proprietary Chinese medicines have passed the 2022 National Medical Insurance Catalogue and have passed the formal review
.
The 35 proprietary Chinese medicines cover 10 treatment categories such as drugs for digestive system diseases, cardiovascular and cerebrovascular diseases, respiratory diseases, pediatric drugs, oncology diseases, and musculoskeletal diseases, and the total sales scale of terminals in China's public medical institutions in 2021 will exceed 9.
3 billion yuan.

Among them, there are 5 varieties of more than 1 billion varieties listed, including Danshen polyphenolate for injection of Green Valley Pharmaceutical, Kangai injection of Changbaishan Pharmaceutical, Conlet injection of Conlite Pharmaceutical, and Lanqin oral liquid of Yangzijiang Pharmaceutical
.
According to Intranet data, the sales scale of terminal proprietary Chinese medicines in China's public medical institutions in 2021 has exceeded 250 billion yuan, an increase of 4.
85%
year-on-year.
With the acceleration of the entry of proprietary Chinese medicines into medical insurance, the 100 billion market may rise again
.
The industry believes that for Chinese medicine companies, how to bring more demonstrable clinical value to patients from traditional medicine is a more important issue
for them to think about.
Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.